Cannabis Agency visits DEMECANs production facility

DEMECAN Standort Nauenhof

Berlin/Dresden, 10. September 2020 – DEMECAN, the only German pharmaceutical producer and wholesaler of medical cannabis, is committed to the nationwide supply of high-quality medical cannabis to patients in Germany.

For this purpose, DEMECAN purchased the production facility of the former cannabis producer Wayland near Dresden and is building Europe's largest indoor production facility for medical cannabis in Europe.

On September 9th, the site was visited by representatives from the German Cannabisagency of the Federal Institute for Drugs and Medical Devices (BfArM). The DEMECAN facility is of high interest to BfArM, as it will ensure that the domestic supply for medicinal cannabis is provided for by a domestic manufacturer.

Established in 2017, BfArM strictly monitors the cultivation of cannabis plants for medical purposes in Germany. The agency must ensure that only cannabis of highest pharmaceutical quality is delivered to pharmacies. In May 2019 DEMECAN was the only domestic company that received a licenset to grow and distribute medical cannabis in Germany. 

Dr. Constantin von der Groeben, Managing Director and co-founder of DEMECAN: "We are delighted that the cannabis agency has visited our production facility. The purchase of the facility was an essential milestone for us in securing the supply of high-quality medical cannabis for patients in Germany".

After completion of its own production facility, DEMECAN will produce medical cannabis Made in Germany as an independent supplier to ensure sufficient availability of medical cannabis for patients in Germany.

About DEMECAN
DEMECAN is the only Germany company that covers all manufacturing steps for medical cannabis – including cultivation, processing, storage and delivering to pharmacies. Dr. Adrian Fischer, Dr. Cornelius Maurer und Dr. Constantin von der Groeben founded DEMECAN in 2017 with the goal of giving patients the access to medicinal cannabis with “Made in Germany” quality. In May 2019 the BfArM awarded DEMECAN a government contract to produce and process medicinal cannabis in Germany. The production and processing of medicinal cannabis will follow the highest pharmaceutical standards. In addition to its German cultivation operations, DEMECAN operates as a cannabis wholesaler and works together with cannabis producers all over the world to import medicinal cannabis that meet the highest pharmaceutical standards. The DEMECAN group has its headquarters in Berlin and is a member of the “Verband der Cannabis versorgenden Apotheken e.V.”

Further information: www.demecan.de
Press contact: press@demecan.de

Weitere Presse­mitteilungen

chevron-downarrow-up